Sign inJoin waitlistJoin the waitlist

EM

Edward Mena

Physician · Edward A. Mena, M.d., Inc

Credentials: · ·

History

Edward A. Mena, M.d., Inc
2026–Present

Gastroenterology
2002–2005
Internal Medicine
1999–2002
Keck Sch of Med of the Univ of Southern Calif
1995–1999

Research

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Journal of Hepatology · 2020 · 209 citations
Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis
Science Translational Medicine · 2019 · 150 citations
Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis
Hepatology · 2023 · 72 citations

Mazen Noureddin
9 papers
SH
Stephen Harrison
6 papers
Naim Alkhouri
5 papers
Naga Chalasani
4 papers
Raj Vuppalanchi
4 papers
Arun Sanyal
3 papers
KL
Kathryn Lucas
3 papers
Michel Mendler
3 papers
TF
Tse-Ling Fong
3 papers
Tsuyoshi Todo
3 papers
AS
Aasim Sheikh
2 papers
AK
Anita Kohli
2 papers

Clinical trials

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
Principal investigator · Unknown · Phase 4
Huntington Medical Research Institutes
2009–2012
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2032
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Site PI · Recruiting · Phase 2
GlaxoSmithKline
2025–2028
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Site PI · Recruiting · Phase 2
GlaxoSmithKline
2024–2028